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REVIEW

Year in review 2010: Critical Care – neurocritical
care
Michael T Scalfani and Michael N Diringer*

Abstract
In 2010 Critical Care published a large number of
articles on critical care aspects of neurologic and
neurosurgical conditions. These aspects included
investigation of diagnostic criteria for bacterial
meningitis, critical illness myopathy and their
relationship to systemic inflammation. A number
of studies investigated the biology of sepsis-related
delirium, its biomarkers, its relationship to inflammation
and its impact on outcome. Other teams reported on
the use of magnetic resonance imaging, biomarkers
and electroencephalogram to predict outcome
in patients who were comatose following cardiac
arrest. Our understanding of the pathophysiology as
well as management of subarachnoid hemorrhage
was addressed in several papers. Topics included
the effect of hemodynamic treatment of delayed
cerebral ischemia, pulmonary edema and the impact
of subarachnoid hemorrhage on endocrine function.
Finally, outcome from neurocritical care and patients’
retrospective willingness to consent to the treatment
they received were reported.

Several important contributions to the ﬁeld of neurocritical care were published in Critical Care during 2010.
These articles can be gathered into six key areas: diagnostic criteria, delirium and encephalopathy, predicting
neurologic outcome after cardiac arrest, subarachnoid
hemorrhage (SAH) and outcome from neurocritical care.

therapy [1], yet distinguishing between bacterial and
nonbacterial meningitis can sometimes prove diﬃcult.
The use of cerebrospinal ﬂuid (CSF) lactate, as opposed
to conventional tests (such as CSF glucose, CSF/plasma
glucose ratio, CSF protein concentration, and CSF
leukocyte count), has been investigated in a number of
studies to distinguish between bacterial and nonbacterial
meningitis.
Huy and coworkers performed a literature review and
meta-analysis to evaluate the usefulness of CSF lactate
concentration for this purpose [2]. From the 25 studies
they identiﬁed, the authors concluded that CSF lactate
alone had a high degree of accuracy in distinguishing
between bacterial and nonbacterial meningitis and
performs better than the conventional tests routinely
used. CSF lactate was found to be less useful if its concentration was low, but when elevated it was helpful,
especially if the diagnosis was otherwise inconclusive.
This suggests that any elevation in CSF lactate
concentration above normal for the assay used could be
employed as a diagnostic marker despite the diﬀerence in
cut-oﬀ values caused by variance in methods, instruments and hospital laboratories. While the authors
conclude CSF lactate is a useful marker to distinguish
between bacterial and nonbacterial meningitis, it is not
meant to replace conventional tests as they are necessary
to diagnose meningitis. Rather, interpretation of lactate
alone is a better discriminator between bacterial and
nonbacterial meningitis than conventional tests. As a
result, measurements of CSF lactate may be considered
part of standard practice to distinguish between bacterial
and nonbacterial meningitis.

Diagnostic criteria
Meningitis

Critical illness myopathy

Favorable outcome from bacterial meningitis requires
rapid diagnosis and immediate initiation of antibiotic

Critical illness myopathy (CIM) frequently complicates
serious illness and often results in prolonged mechanical
ventilation. This complication is characterized by the
atrophy of type II muscle ﬁbers and thick ﬁlaments, as
well as nonexcitable muscle membranes [3]. Risk factors
for developing CIM are not well understood.
Weber-Carstens and colleagues performed a prospective observational study of 40 ICU patients with a
Simpliﬁed Acute Physiology Score II ≥20 to identify risk
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factors for CIM. Patients were evaluated on three consecutive days within 1 week of ICU admission [4]. The
authors investigated demographics, inﬂammatory, metabolic and hemodynamic parameters, and medical treatment prior to the ﬁrst nonelectromyography signs of
CIM. On univariate analysis, inﬂammation, disease
severity, decreased insulin sensitivity, catecholamine use
and sedation requirements were all signiﬁcantly associated with CIM. Low-dose hydrocortisone treatment in
septic shock and administration of neuromuscular
blocking agents or aminoglycosides, however, were not
related to CIM. In a multivariate Cox proportional
hazard regression analysis, IL-6 was the only independent
risk factor for CIM (95% conﬁdence interval (CI) = 1.00
to 1.01; P = 0.005); however, the overall eﬀect was small.
The authors hypothesize that impairment of growthfactor-mediated intracellular signaling induced by
systemic inﬂammation is important in the pathophysiology of CIM. A weakness of this study was that subject
blood samples were only taken at two separate time
points, which makes it impossible to determine the daily
course of the inﬂammatory parameters.

Delirium/encephalopathy
In hospitalized patients, delirium is associated with
increased mortality, length of stay and cost [5,6]. The
epidemiology of delirium in ICUs is poorly understood,
however, in part because its evaluation has been limited
to single-center studies. Salluh and coworkers performed
a 1-day point-prevalence study in 104 ICUs [7]. Patients
were excluded if they had Glasgow Coma Scale (GCS)
<14 from a primary neurologic diagnosis, were legally
blind or deaf, could not speak the language of the country
where the ICU was located, or were moribund. Of the
975 patients screened, only 497 were enrolled. Because of
the use of sedative drugs, only 232 (46.6%) of the enrolled
patients could be evaluated. Of the patients evaluated, 75
met the diagnostic criteria for delirium using the Confusion Assessment Method for the ICU. The authors found
delirium to be associated with higher mortality, and
longer ICU and hospital length of stays. This suggests
that sicker patients have a higher risk of developing
delirium, as well as a higher risk of staying longer or
dying in the ICU. The main modiﬁable risk factors were
the use of invasive devices and sedatives (midazolam).
This study conﬁrmed ﬁndings from single-center studies
indicating that delirium is common in ICU patients and
is associated with longer length of stay and adverse
outcomes. Important weaknesses of this study are the
high number of patients excluded and that so many
patients could not be assessed due to sedation. Hence,
only 24% of those patients originally screened were
evaluated for delirium. This raises an important question
of whether we are sedating too many patients in the ICU.
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In addition, the true incidence of delirium in the ICU is
diﬃcult to determine from this study due to the exclusion
of the majority of patients.
Another important insight into delirium was reported
by Mu and colleagues in a prospective cohort study [8].
In postoperative patients who had undergone coronary
artery bypass graft surgery they measured serum cortisol
levels and assessed their relationship to delirium. A total
of 243 patients were assessed for delirium twice daily
during the ﬁrst ﬁve postoperative days using the
Confusion Assessment Method for the ICU. The presence
of delirium was compared with serum cortisol measured
on the morning of the ﬁrst postoperative day.
Postoperative delirium was identiﬁed in 50% of patients
(n = 123). A high serum cortisol level (odds ratio (OR) =
3.09, 95% CI = 1.76 to 5.41, P <0.001), occurrence of
complications during the ﬁrst day after surgery (OR =
2.49, 95% CI = 1.18 to 5.21, P = 0.016), a history of
diabetes mellitus (OR = 1.91, 95% CI = 1.00 to 3.62, P =
0.049), prolonged duration of surgery (OR = 1.36, 95% CI
= 1.01 to 1.83, P = 0.043) and increasing age (OR = 1.11,
95% CI = 1.06 to 1.16, P <0.001) were all associated with
increased risk of postoperative delirium. Postoperative
delirium was also associated with increased length of stay
and with worse outcome.
This study has some limitations. Serum cortisol levels
were not measured at baseline and were measured only
once after surgery. As a result the data could potentially
be skewed prior to surgery by including patients who had
elevated cortisol and who might have been at greater risk
of developing postoperative delirium due to preexisting
conditions. In addition, the investigators did not perform
baseline psychiatric or cognitive screening tests. Any
mental disorders present prior to surgery could inﬂuence
the development of postoperative delirium.
Systemic infections can cause serious cognitive dysfunction in ICU patients, which may be related to
proinﬂammatory cytokines. IL-1 is a likely cytokine
candidate due to its inﬂuence on both the immune
system as well as the central nervous system. To address
this question, Terrando and colleagues investigated the
development of LPS-induced cognitive dysfunction in
wild-type and IL-1 knockout mice [9]. After lipopolysaccharide (LPS) challenge, performance on behavioral
tests of memory and response to novel environments
deteriorated and reactive microgliosis was seen in the
hippocampus. In addition, plasma TNFα, IL-1β, IL-6,
and high-mobility group box-1, IL-6 and IL-1β mRNA all
increased. Administration of IL-1 receptor antagonist
signiﬁcantly reduced plasma cytokines and hippocampal
microgliosis, and ameliorated cognitive dysfunction;
similar results were seen in IL-1 knockout mice without
receiving IL-1 receptor antagonist. These data suggest
that behavioral dysfunction could be prevented by
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blocking the IL-1 signal, attenuating the inﬂammatory
cascade. Future studies would need to be carried out to
determine whether responses are seen in patients.
Sepsis-associated encephalopathy (SAE) is deﬁned as
diﬀuse cerebral dysfunction that is caused by a systemic
response to infection without any evidence of a central
nervous system infection [10,11]. However, the pathophysiology of SAE is not well understood. In a prospective cohort study, Berg and colleagues found that
brain function might be impaired during systemic inﬂammation due to a reduction in the plasma ratio
between branched-chain amino acids and aromatic
amino acids (BCAA/AAA ratio), which alters their
uptake into the brain [12]. Twelve healthy adult male
subjects (aged 20 to 33) were enrolled. After an overnight
fast, all subjects underwent measurements of cerebral
blood ﬂow (CBF), plasma BCAA/AAA ratio, cerebral
delivery, net exchange of large amino acids and ammonia
level. Paired arteriojugular venous blood samples were
taken at baseline and after a 4-hour continuous
intravenous infusion of puriﬁed Escherichia coli LPS.
This LPS infusion resulted in an increase in plasma
phenylalanine and a signiﬁcant decrease in the
concentration of all other large neutral amino acids
except for isoleucine. As the BCAA/AAA ratio decreased,
there was an increase in the levels of the neurotoxic AAA
phenylalanine – suggesting a relationship to encephalopathy. In this study, however, the investigators did not
perform cognitive tests on the subjects. Therefore, while
systemic inﬂammation may aﬀect brain function by
reducing the BCAA/AAA ratio, it is diﬃcult to draw any
conclusions regarding the role of the BCAA/AAA ratio in
SAE until cognitive function is assessed.
In another study investigating the pathophysiology of
SAE, Szatmári and colleagues assessed cerebrovascular
reactivity using an acetazolamide challenge in SAE
patients [13]. In a prospective cohort, patients with
clinical sepsis and disturbances of consciousness of any
degree were studied. In addition, 20 age-matched and
sex-matched controls without previous diseases aﬀecting
cerebral vasoreactivity were also included. Transcranial
Doppler blood ﬂow velocities were then measured at
baseline and 5, 10, 15 and 20 minutes after intravenous
administration of 15 mg/kg acetazolamide. The time
course of the CBF velocity response to acetazolamide was
measured and cerebrovascular reactivity was calculated
(the percentage increase in the mean blood ﬂow velocity).
In addition, the maximum vasodilatory eﬀect (cerebrovascular reserve capacity) was determined. The authors
found that the time course of the vasomotor reaction to
acetazolamide was delayed and the maximal vasodilatory
response was reduced in SAE patients. The authors
propose that cerebral hemodynamic changes might be
involved in early pathogenesis of SAE.
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SAE is common in patients with septic shock and has
been associated with elevated levels of brain-speciﬁc
S100β protein. In some studies, treatment of septic
patients with drotrecogin alfa (DrotAA) reduces mortality in patients with severe sepsis-induced organ failure.
Spapen and coworkers sought to determine whether
DrotAA would reduce S100β levels and sepsis-associated
encephalopathy [14]. Patients with pre-existing or acute
neurological disorders were excluded. Those enrolled
were classiﬁed into two groups based on their level of
consciousness: GCS ≥13 and GCS <13. DrotAA was
given as a continuous infusion of 24 μg/kg/hour for
96 hours. The level of S100β was measured before
sedation and serially after the start of DrotAA infusion.
Of the 54 patients in the study, one-half had elevated
S100β levels. In patients with GCS <13 receiving DrotAA,
S100β levels fell from baseline at 64 and 96 hours (both
P <0.05). In addition, those who received DrotAA had
signiﬁcantly lower S100β levels at 64 and 96 hours
compared with those who did not receive treatment. In
patients with GCS ≥13, however, DrotAA had no eﬀect
on S100β levels. These data suggest an association
between the severity of SAE and serum levels of S100β,
but the measure of encephalopathy was limited.

Cardiac arrest
Our ability to predict neurological outcome of patients
who remain comatose following cardiac arrest is limited.
In addition, the existing data must be re-evaluated due to
advent of treatment with hypothermia. Choi and colleagues
sought to determine whether diﬀusion-weighted magnetic
resonance imaging (MRI) could improve prediction of
outcome [15]. They studied 39 patients who suﬀered outof-hospital cardiac arrest, performing diﬀusion-weighted
MRI within 5 days of cardiac arrest and then comparing
functional outcome at 3 months. Patients were treated
with hypothermia in the latter half of the study, limiting
interpretation. Diﬀusion-weighted MRI ﬁndings were
categorized into four patterns: normal, isolated cortical
injury, isolated deep gray nuclei injury, and mixed injury
(cortex and deep gray nuclei). Twenty-three subjects with
normal MRI scans served as controls. The authors found
that a mixed pattern of brain injury involving cortex and
deep gray nuclei on MRI predicted an unfavorable
outcome, deﬁned as a Glasgow Outcome Scale (GOS)
score of 1 to 3.
Another approach to predicting neurological outcome
of cardiac arrest patients involved the use of serum
biomarkers. Steﬀen and colleagues investigated the
ability of neuron-speciﬁc enolase to predict outcome
from cardiac arrest treated with hypothermia [16].
Ninety-seven subjects were compared with 133 historical
cardiac arrest patients not treated with hypothermia. In
this observational prospective cohort study, serum
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neuron-speciﬁc enolase was measured 72 hours after
ICU admission and the neurological outcome (Pittsburgh
cerebral performance category) was recorded at ICU
discharge. In univariate analysis, neuron-speciﬁc enolase
serum levels were lower in patients treated with hypothermia. The 72-hour neuron-speciﬁc enolase cut-oﬀ
levels, however, did not reliably predict poor neurological
outcome. The authors also note that 1-year survival was
signiﬁcantly higher for the hypothermia group compared
with the historical nonhypothermic controls.
Rossetti and coworkers focused on the use of continuous electroencephalogram (EEG) to predict outcome
in cardiac arrest patients treated with hypothermia [17].
In a cohort of 34 patients, continuous EEG demonstrating nonreactive or discontinuous background during
hypothermia was strongly associated with unfavorable
outcome in their patients. In addition, nonreactive
background EEG was 100% predictive of mortality (95%
CI = 74 to 100%) with a false-positive rate of 0 (95% CI =
0 to 18%). These data suggest that early continuous EEG
ﬁndings might be a better predictor of outcome than
biomarkers or imaging.

Spontaneous aneurysmal subarachnoid
hemorrhage
The most common and potentially treatable cause of
secondary neurological injury after aneurysmal SAH is
delayed cerebral ischemia (DCI). DCI occurs several days
after hemorrhage and is considered to result from
reductions in CBF below critical ischemic thresholds.
Several factors are thought to contribute to DCI
including large artery vasospasm, impaired cerebral
autoregulation and intravascular volume depletion [18].
Triple-H therapy (hypervolemia, hypertension, hemodilution) is the mainstay treatment of DCI with the goal
of increasing cerebral perfusion pressure. Dankbaar and
colleagues performed a systematic review of the literature
addressing the eﬀectiveness of triple-H therapy and its
components on clinical outcome [19]. Eleven studies of
triple-H therapy were identiﬁed and included in their
meta-analysis. The authors concluded that hemodilution
did not change CBF and that only one of the seven
studies on hypervolemia showed a signiﬁcant increase in
CBF. There was a signiﬁcant increase in CBF in two of the
four studies applying hypertension and in one study using
triple-H therapy. None of these studies used control
groups or randomization. The authors conclude that
there is no evidence from controlled studies for a
beneﬁcial eﬀect of triple-H therapy or its separate
components on CBF in SAH patients.
The conclusion that there is no evidence to support
triple-H therapy is misleading, however, as the treatment
has not been properly studied to date. This systematic
review points out the lack of well-designed studies.
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Owing to the amount of underpowered and poorly
designed studies, it is diﬃcult to come to any conclusions
regarding eﬀectiveness.
In a prospective cohort study, Bendel and coworkers
evaluated neuroendocrine status after SAH and its impact
on clinical outcome [20]. They enrolled 30 subjects and 16
controls. The study focused on insulin-like growth factor-1
(IGF-1), which is associated with neuronal growth, cell
death and apoptosis after ischemic stroke [21]. The
authors found that serum IGF-1 concentrations were
signiﬁcantly lower in SAH patients on days 1 to 5 compared with controls (P = 0.01). There was no signiﬁcant
diﬀerence at 3 months between the groups. In addition,
there was no relationship between the severity of SAH
and the IGF-1 concentration. The data showed patients
with GOS ≤4 had lower IGF-1 concentrations and lower
health-related quality of life compared with patients with
higher GOS scores. This is the ﬁrst published study to
evaluate IGF-1 in the acute phase of aneurysmal SAH.
The authors suggest that low IGF-1 following SAH might
be associated with poor outcome or death.
Pulmonary edema is common after SAH [22], but its
management is complicated by the need to rigorously
avoid hypovolemia in these patients. Hoﬀ and colleagues
prospectively studied intravascular volume (using pulse
dye densitometry) in 102 SAH patients, comparing those
with and without pulmonary edema [23]. Surprisingly,
those patients who developed pulmonary edema (17 out
of 102) had lower mean circulating blood volume than
those without. As a result, ﬂuid management in SAH
patients that develop pulmonary edema is more diﬃcult.
The authors concluded that treatment for pulmonary
edema with diuresis must be weighed against the risk of
worsening hypovolemia in SAH patients and thus
increasing the risk of DCI.

Outcome from neurocritical care
Despite advances in diagnosis and treatment, patients
admitted to a neurocritical care unit have poor functional
outcome and high mortality [24]. In a retrospective
review of 796 consecutive patients admitted to a nonsurgical neurocritical care unit, Kiphuth and colleagues
found an in-hospital mortality of 22.5%. Good long-term
functional outcome (determined by the modiﬁed Rankin
Scale) was seen in only 28.4% [25]. Variables found to be
independently associated with outcome were admission
diagnosis, age, duration of mechanical ventilation and
Therapeutic Intervention Scoring System-28 on day 1.
When diagnoses were compared, the authors found that
patients with Guillain–Barré syndrome and myasthenia
gravis had a good long-term outcome more often than
those with other diagnoses.
In another study, Kiphuth and colleagues investigated
the relationship between functional outcome and
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retrospective agreement to neurocritical care [26]. The
purpose of this study was to determine whether retrospective consent to neurocritical care was inﬂuenced by
functional outcome. In this study of 704 consecutive
patients admitted to a nonsurgical neurocritical care
unit, 91% of patients who were independent at 1 year
would again agree to the care they received. Only 19% of
those who were dependent for activities of daily living,
however, would have agreed retrospectively to
neurocritical care. The authors conclude that eﬀorts must
be taken to increase public awareness regarding the
importance of advanced directives, and further research
must focus on determining highly speciﬁc and sensitive
predictors for outcome in these patients.
In patients suﬀering from nontraumatic supratentorial
intracerebral hemorrhage, the inﬂuence of anemia on
functional outcome and mortality was investigated by
Diedler and colleagues. In a retrospective cohort study of
196 patients, 23.5% had a favorable outcome (moderate
disability or better) [27]. The mean hemoglobin concentration was signiﬁcantly lower (12.3 versus 13.7 g/dl,
P <0.001) in those with poor outcome. On multivariate
analysis, the independent predictors of poor outcome at
90 days were mean hemoglobin, age and NIH Stroke
Scale score on admission. The authors conclude, however,
that they could not determine whether anemia causes
further brain injury or is a marker of severe injury.
Despite the diﬀerence in mean hemoglobin in those
patients with poor outcome, this is of uncertain clinical
signiﬁcance.
Outcome after traumatic brain injury is diﬃcult to
predict. Recent investigations have looked into a variety
of biomarkers to better predict and monitor outcome
after brain trauma. Biomarkers investigated include glial
ﬁbrillary acidic protein [28], neuroﬁlament light chain
[29], S100 [30], tissue transglutaminases [31], ubiquitin
[32], β-amyloid precursor proteins [33] and tau [34].
Dong and colleagues investigated the use of the biomarker resistin predicting outcome after traumatic brain
injury. This group previously reported that elevated levels
of resistin are found in blood of patients with
intracerebral hemorrhage and that higher levels were
associated with poor outcome. The authors subsequently
studied a cohort of 94 patients with severe traumatic
brain injury and compared their resistin levels with those
of 50 healthy controls [35]. Plasma resistin levels were
elevated during the initial 6 hours after injury and peaked
within 24 hours; the patients’ levels were substantially
higher than those of the healthy controls. Plasma resistin
levels were negatively correlated with GCS (P <0.001)
and were an independent predictor of 1-month survival.
The data suggest that the plasma resistin level might
reﬂect the initial brain injury and could become a useful
biomarker to predict survival in these patients.
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Conclusion
In 2010 the ﬁeld of neurocritical care received increased
attention, with an increasing number of articles being
published in Critical Care. The issues of diagnostic
criteria for meningitis and critical illness myopathy were
further investigated. In addition, studies of the epidemiology, risk factors, and treatment for delirium and
encephalopathy in the ICU were published. Aspects of
cardiac arrest, aneurysmal SAH and outcomes in neurocritical care were re-addressed using new approaches.
Overall, there were many quality articles published in
Critical Care during 2010 that have added to our
scientiﬁc and clinical knowledge in the ﬁeld of
neurocritical care.
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